Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (600 mg Loading Dose Followed by 150 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects

Primary objective:

• Assess the effects of clopidogrel (600 mg loading dose followed by 4 days 150 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to given alone in healthy male and female subjects

Secondary Objective:

• Compare the pharmacokinetic profiles of clopidogrel and its active metabolite when clopidogrel is given either alone or concomitantly with omeprazole

The total study duration per subjects is 8 - 9 weeks broken down as follows:

• Screening: 2 to 21 days before the first dosing (clopidogrel or omeprazole)
• Period clopidogrel/placebo: 7 days including 5 days treatment
• Period clopidogrel/placebo + omeprazole: 12 days including 10 days treatment
• Washout between periods: at least 14 days after last dosing with respect to clopidogrel treatment
• End of study: 7 to 10 days after the last dosing

Inclusion Criteria:

Healthy subject:

• as determined by medical history, physical examination including vital signs and clinical laboratory tests:
• with a body weight between 50 kg and 95 kg if male, between 40 kg and 85 kg if female, and with a Body Mass Index (BMI) between 18 and 30 kg/m²

Exclusion Criteria:

• Evidence of inherited disorder of coagulation/hemostasis functions
• Smoking more than 5 cigarettes or equivalent per day
• Abnormal hemostasis screen
• Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration >Any contraindication to clopidogrel and/or omeprazole

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.